Cullinan Oncology LLC (CGEM) Stock Analysis

Cullinan Oncology LLC (CGEM) is a publicly traded company in the HEALTHCARE sector. It trades at $18.38, carries a market capitalization of $1.12B. This page summarizes the public market data, fundamentals, and frequently asked questions for CGEM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Price: $18.38
Market Cap: $1.12B
EPS: $-3.37
52-Week High: $19.43
52-Week Low: $5.68

Market Sentiment

Cullinan Oncology LLC currently has a Neutral sentiment score of 0.03.

About Cullinan Oncology LLC

Cullinan Oncology LLC is a dynamic biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on pioneering targeted oncology and immuno-oncology therapies to enhance outcomes for cancer patients. Committed to innovation and strategic partnerships, Cullinan is developing a diverse pipeline of therapeutic candidates that address significant unmet medical needs in the oncology sector. By harnessing state-of-the-art science and technology, the company aims to revolutionize canc...

GNG Research Analysis

GNG Research scores Cullinan Oncology LLC (CGEM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CGEM.

Frequently Asked Questions

Does CGEM pay dividends?

Cullinan Oncology LLC (CGEM) does not currently pay a regular dividend.

What is CGEM's market cap?

Cullinan Oncology LLC (CGEM) has a market capitalization of $1.12B with a current stock price of $18.38.